A Clinical Study on the Prevention of Mild to Moderate Intermittent Asthma With Chinese Medicine … (NCT04522726) | Clinical Trial Compass
UnknownPhase 2
A Clinical Study on the Prevention of Mild to Moderate Intermittent Asthma With Chinese Medicine Weiyang Yuping Fang
China84 participantsStarted 2020-10-01
Plain-language summary
Clinical exploring study of Weiyang Yuping Decoction in preventing acute attacks of mild to moderate intermittent asthma Based on the theory of "Preventing disease from exacerbating" in Chinese medicine.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of asthma according to GINA criteria with a documented history of at least 3 years prior to Visit 1
* Patients have asthma exacerbations every year
* Meet the diagnostic criteria for mild to moderate asthma
* Able to measure lung ventilation function according to ATS (American Thoracic Society) standards
* Patients who have given written informed consent
Exclusion Criteria:
* Medical history of life-threatening asthma including intubation and intensive care unit admission
* Any significant disease or disorder (e.g., cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
* Pregnancy, breast-feeding or planned pregnancy during the study.
* Participation in another clinical study or took other research drugs during the last 30 days prior to Visit 1
* Known or suspected hypersensitivity to study drugs or excipient
* Suspected poor capability, as judged by the investigator, of following instructions of the study.
What they're measuring
1
Annual severe asthma exacerbation rate
Timeframe: up to 12 months after treatment
Trial details
NCT IDNCT04522726
SponsorShanghai University of Traditional Chinese Medicine